ICPT News and Press, Intercept Pharmaceuticals Inc. From 11/01/22

Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) were soaring 15.7% higher as of 12:02 p.m. ET on Tuesday. The big gain came after the drugmaker announced its third-quarter results before the market opened. Intercept reported Q3 revenue of $77.6 million, up 16.5% year over yea...

Intercept Pharma ( NASDAQ: ICPT ) is trading ~12% higher after the company raised Ocaliva adjusted net sales guidance and posted a 16% rise in quarterly profit, helped by strong sale of Ocaliva treatment Primary biliary cholangitis treatment Ocaliva net sale...

Intercept Pharma press release ( NASDAQ: ICPT ): Q3 EPS of -$3.04 may not be comparable to consensus of $6.00. Revenue of $77.59M (+16.4% Y/Y). Company increases 2022 Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million and narrows non-GAAP adju...

U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter Company increases 2022 Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million and narrows non-GAAP adjusted operating expense guidance to $350 million to $365 million ...

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis demonstrating improvement in outcomes, including transplant-free survival, for PBC patien...

Summary Akero recently presented data which did not follow an intent-to-treat (ITT) analysis. They admitted this would have made them miss at least one endpoint. The company twice now has not let investors see all the data from its clinical studies. There are other issues with...

MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 f...

MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President a...

While the overall markets remained focused on macro issues, a handful of stocks saw dramatic moves on company-specific news during Friday's midday trading. The list included Intercept ( NASDAQ: ICPT ), which posted a double-digit percentage loss following the release of clinical tri...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Pavel Kapysh / Shutterstock Arcimoto (NASDAQ: FUV ) stock is on a wild ride today after the electric vehicle (EV) company revealed plans for a strategic restructuring. According to a filing with the U...